The spectrum of mutations substantially overlapped with that of overt hematologic neoplasms—in particular, myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs)—with the epigenetic modifier genes DNMT3A, TET2, and ASXL1 and the tyrosine kinase gene JAK2 being most frequently mutated [4]. This evidence concerns the gene JAK2 and myeloproliferative disorder.